The Experts below are selected from a list of 3075 Experts worldwide ranked by ideXlab platform
Livio Luzi - One of the best experts on this subject based on the ideXlab platform.
-
Overview of Cellular Transplantation in Diabetes Mellitus: Focus on the Metabolic Outcome
Advances in Endocrinology, 2015Co-Authors: Livio Luzi, Stefano Benedini, Andrea Caumo, Ileana TerruzziAbstract:Diabetes mellitus is a metabolic disease possible to treat via several different therapeutic approaches. Since the advent of insulin in 1922, type 1 diabetes mellitus has become a chronic treatable disease. Nonetheless, type 1 diabetes mellitus can be a devastating disease when the macro- and microangiopathic complications take place after several years of illness. Starting from the eighties, Pancreas/Islet Transplantation has become a potential innovative treatment of diabetes mellitus. The major advantage of Pancreas/Islet Transplantation is the restoration of c-peptide cosecretion along with insulin; the major disadvantage is the need to administer immunosuppressive drugs which are diabetogenic themselves. Islet Transplantation is the progenitor of more recent forms of cellular and stem cell therapies which will be reviewed herein. Cellular therapies for diabetes mellitus are still an experimental procedure. Herein we present the actual current achievements and an outlook of close future possible advancements in the area of cellular Transplantation for the cure of diabetes mellitus.
-
Immunosuppressive therapy in Pancreas and Islet transplant: Need for simultaneous assessment of insulin sensitivity and secretion *
Journal of Diabetes Mellitus, 2013Co-Authors: Stefano Benedini, Andrea Caumo, Leana Terruzzi, Livio LuziAbstract:Diabetes mellitus is a metabolic disease possible to treat via Pancreas/Islet Transplantation but most immunosuppressive drugs are diabetogenic. In this letter, we review current up to date methods to assess insulin action and secretion (using the surrogate indexes) suggesting their use in large studies in populations of Pancreas/ Islets transplanted patients.
Forrest Dodson - One of the best experts on this subject based on the ideXlab platform.
-
Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients.
Transplantation proceedings, 1995Co-Authors: A. Zeevi, Paulo Fontes, Abdul S. Rao, R. Shapiro, M. Pavlick, S. Lombardozzi, Richard A. Banas, Anthony J. Demetris, Mark L. Jordan, Forrest DodsonAbstract:BONE MARROW (BM) augmentation of donor-derived chimerism was achieved in recipients of kidney, liver, heart, and Pancreas Islet Transplantation.1 We have proposed that these donor-derived cells are essential for graft acceptance and the induction of donor-specific nonreactivity.2,3 The first 15 BM-augmented transplant recipients and 16 nonmarrow controls who were more than 120 days posttransplant underwent sequential in vitro immunological evaluations to determine the development of donor-specific hyporeactivity.4 Based on proliferative responses (pre- and posttransplant) of peripheral blood mononuclear cells (PBMCs) to mitogens and alloantigens, the recipients were classified into four categories: donor-specific hyporeactive, intermediate, responsive, and suppressed.4 Fifty-three percent of BM treated recipients (eight of 15) exhibited progressive modulation of antidonor responses, whereas only 12% of nonmarrow controls showed donor-specific hyporeactivity. However, the follow-up time in the nonmarrow control group was shorter (112 ± 10 days) as compared with that of patients in the study group (282 ± 113 days).4 In this report, we reanalyzed the immune profile of BM-treated and nonmarrow controls 3 months later, and the results were compared with the earlier report.
-
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and Pancreas Islet Transplantation
The Lancet, 1994Co-Authors: Paulo Fontes, Abdul S. Rao, Patricia B. Carroll, Forrest Dodson, R. Shapiro, A. G. Tzakis, S. Todo, Kareem Abu-elmagd, M Jordon, J. J. FungAbstract:Abstract Summary We have previously postulated that donor cell chimerism in organ Transplantation is needed to attain a tolerant state. Here we show that donor cell chimerism can be augmented in organ recipients if they are infused perioperatively with 3 x 10 8 per kg of unmodified donor bone marrow cells and are kept on a conventional immunosuppressive regimen of tacrolimus (FK506) and prednisolone. 36 patients took part, of whom the first 18 patients have good transplanted kidney (n=10), liver (n=7), and heart (n=7) function when followed up between 4 and 16 months. All patients are well. We found persistent multilineage leucocyte chimerism in blood of 17 recipients by flow cytometry and PCR techniques to detect donor alleles or Y chromosomes in female recipients of male organs. The use of the 5-antigen HLA matched same sex donor precluded detection of chimerism in one patient.
Paulo Fontes - One of the best experts on this subject based on the ideXlab platform.
-
Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients.
Transplantation proceedings, 1995Co-Authors: A. Zeevi, Paulo Fontes, Abdul S. Rao, R. Shapiro, M. Pavlick, S. Lombardozzi, Richard A. Banas, Anthony J. Demetris, Mark L. Jordan, Forrest DodsonAbstract:BONE MARROW (BM) augmentation of donor-derived chimerism was achieved in recipients of kidney, liver, heart, and Pancreas Islet Transplantation.1 We have proposed that these donor-derived cells are essential for graft acceptance and the induction of donor-specific nonreactivity.2,3 The first 15 BM-augmented transplant recipients and 16 nonmarrow controls who were more than 120 days posttransplant underwent sequential in vitro immunological evaluations to determine the development of donor-specific hyporeactivity.4 Based on proliferative responses (pre- and posttransplant) of peripheral blood mononuclear cells (PBMCs) to mitogens and alloantigens, the recipients were classified into four categories: donor-specific hyporeactive, intermediate, responsive, and suppressed.4 Fifty-three percent of BM treated recipients (eight of 15) exhibited progressive modulation of antidonor responses, whereas only 12% of nonmarrow controls showed donor-specific hyporeactivity. However, the follow-up time in the nonmarrow control group was shorter (112 ± 10 days) as compared with that of patients in the study group (282 ± 113 days).4 In this report, we reanalyzed the immune profile of BM-treated and nonmarrow controls 3 months later, and the results were compared with the earlier report.
-
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and Pancreas Islet Transplantation
The Lancet, 1994Co-Authors: Paulo Fontes, Abdul S. Rao, Patricia B. Carroll, Forrest Dodson, R. Shapiro, A. G. Tzakis, S. Todo, Kareem Abu-elmagd, M Jordon, J. J. FungAbstract:Abstract Summary We have previously postulated that donor cell chimerism in organ Transplantation is needed to attain a tolerant state. Here we show that donor cell chimerism can be augmented in organ recipients if they are infused perioperatively with 3 x 10 8 per kg of unmodified donor bone marrow cells and are kept on a conventional immunosuppressive regimen of tacrolimus (FK506) and prednisolone. 36 patients took part, of whom the first 18 patients have good transplanted kidney (n=10), liver (n=7), and heart (n=7) function when followed up between 4 and 16 months. All patients are well. We found persistent multilineage leucocyte chimerism in blood of 17 recipients by flow cytometry and PCR techniques to detect donor alleles or Y chromosomes in female recipients of male organs. The use of the 5-antigen HLA matched same sex donor precluded detection of chimerism in one patient.
Stefano Benedini - One of the best experts on this subject based on the ideXlab platform.
-
Overview of Cellular Transplantation in Diabetes Mellitus: Focus on the Metabolic Outcome
Advances in Endocrinology, 2015Co-Authors: Livio Luzi, Stefano Benedini, Andrea Caumo, Ileana TerruzziAbstract:Diabetes mellitus is a metabolic disease possible to treat via several different therapeutic approaches. Since the advent of insulin in 1922, type 1 diabetes mellitus has become a chronic treatable disease. Nonetheless, type 1 diabetes mellitus can be a devastating disease when the macro- and microangiopathic complications take place after several years of illness. Starting from the eighties, Pancreas/Islet Transplantation has become a potential innovative treatment of diabetes mellitus. The major advantage of Pancreas/Islet Transplantation is the restoration of c-peptide cosecretion along with insulin; the major disadvantage is the need to administer immunosuppressive drugs which are diabetogenic themselves. Islet Transplantation is the progenitor of more recent forms of cellular and stem cell therapies which will be reviewed herein. Cellular therapies for diabetes mellitus are still an experimental procedure. Herein we present the actual current achievements and an outlook of close future possible advancements in the area of cellular Transplantation for the cure of diabetes mellitus.
-
Immunosuppressive therapy in Pancreas and Islet transplant: Need for simultaneous assessment of insulin sensitivity and secretion *
Journal of Diabetes Mellitus, 2013Co-Authors: Stefano Benedini, Andrea Caumo, Leana Terruzzi, Livio LuziAbstract:Diabetes mellitus is a metabolic disease possible to treat via Pancreas/Islet Transplantation but most immunosuppressive drugs are diabetogenic. In this letter, we review current up to date methods to assess insulin action and secretion (using the surrogate indexes) suggesting their use in large studies in populations of Pancreas/ Islets transplanted patients.
Ileana Terruzzi - One of the best experts on this subject based on the ideXlab platform.
-
Overview of Cellular Transplantation in Diabetes Mellitus: Focus on the Metabolic Outcome
Advances in Endocrinology, 2015Co-Authors: Livio Luzi, Stefano Benedini, Andrea Caumo, Ileana TerruzziAbstract:Diabetes mellitus is a metabolic disease possible to treat via several different therapeutic approaches. Since the advent of insulin in 1922, type 1 diabetes mellitus has become a chronic treatable disease. Nonetheless, type 1 diabetes mellitus can be a devastating disease when the macro- and microangiopathic complications take place after several years of illness. Starting from the eighties, Pancreas/Islet Transplantation has become a potential innovative treatment of diabetes mellitus. The major advantage of Pancreas/Islet Transplantation is the restoration of c-peptide cosecretion along with insulin; the major disadvantage is the need to administer immunosuppressive drugs which are diabetogenic themselves. Islet Transplantation is the progenitor of more recent forms of cellular and stem cell therapies which will be reviewed herein. Cellular therapies for diabetes mellitus are still an experimental procedure. Herein we present the actual current achievements and an outlook of close future possible advancements in the area of cellular Transplantation for the cure of diabetes mellitus.
